Physician profile
M Tarek Orfaly
NPI 1578566931
$3,436.05
in general payments reported to CMS, 2019-2025
27 companies · $750 in 2025
The $750 reported for 2025 was more than what a typical Otolaryngic Allergy provider received nationally (typical 2025 total: $449).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $158 · 2021: $503 · 2022: $596 · 2023: $856 · 2024: $442 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,048.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $887.89 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $496.05 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $406.27 | 2021-2025 | Nucala |
| Alk-Abello, INC | $255.26 | 2019-2025 | Timothy, Standardized, Standardized Mite D. Farinae, Alternaria Tenuis |
| Takeda Pharmaceuticals U.S.A., INC. | $242.35 | 2022-2024 | Cuvitru |
| Biocryst US Sales Co., LLC | $130.87 | 2024-2025 | Orladeyo |
| Lundbeck LLC | $129.66 | 2023-2025 | Vyepti |
| Pfizer INC. | $128.21 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $107.57 | 2021-2022 | |
| Aerin Medical INC. | $78.78 | 2024-2025 | |
| Abbvie INC. | $65.59 | 2023-2025 | |
| Acclarent, INC | $60.69 | 2019-2021 | |
| Stryker Corporation | $57.38 | 2021-2022 | |
| Greer Laboratories, INC. | $55.69 | 2025 | Oralair |
| Integra Lifesciences Corporation | $53.53 | 2024-2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $35.76 | 2020 | |
| Hikma Pharmaceuticals USA | $34.73 | 2022-2023 | Ryaltris |
| Merck Sharp & Dohme LLC | $32.99 | 2021-2023 | |
| Genentech USA, INC. | $24.95 | 2022 | |
| Supernus Pharmaceuticals, INC. | $24.09 | 2021 | |
| Optinose US, INC. | $21.11 | 2021 | |
| Ethicon US, LLC | $20.16 | 2022 | |
| Watermark Medical, INC. | $20.14 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $18.53 | 2025 | |
| Smith+Nephew, INC. | $17.29 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $16.16 | 2022 | |
| Olympus America INC. | $14.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw M Tarek Orfaly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.